Temozolomide
Pronunciation: te-mo-ZOL-oh-mide
An oral alkylating chemotherapy agent used in treating pancreatic neuroendocrine tumors, often combined with capecitabine.
Full Definition
Temozolomide is an oral alkylating agent that methylates DNA, leading to cell death. Originally developed for brain tumors, it has shown efficacy in pancreatic neuroendocrine tumors, particularly those with mutations in DNA repair genes like MGMT. The drug is frequently used in combination with capecitabine (CAPTEM regimen) for advanced or metastatic pancreatic NETs. Common side effects include myelosuppression, fatigue, and nausea. The medication requires careful monitoring of blood counts and may cause delayed hematologic toxicity that can persist for weeks after treatment discontinuation.
Usage
Usage note: Brand name Temodar should be capitalized; generic temozolomide is lowercase.
In Context
- "The patient was started on temozolomide 150 mg/m² daily for 5 days every 28 days for progressive pancreatic NET." — Chemotherapy protocol
- "Temozolomide therapy was held due to grade 3 thrombocytopenia on cycle 3 day 21 labs." — Toxicity management